Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Jun
26
2018
Ninth Circuit Confirms that Class Action Plaintiffs Must Plausibly Establish Future Intent To Re-Purchase To Maintain Claims for Injunctive Relief Sheppard, Mullin, Richter & Hampton LLP
Jan
11
2022
Day One Notes for the 40th Annual J.P. Morgan Healthcare Conference, 2022 Sheppard, Mullin, Richter & Hampton LLP
May
1
2019
Yes, UCANN! Sheppard, Mullin, Richter & Hampton LLP
Oct
5
2022
Takeaways From the U.S. Patent and Trademark Office’s Artificial Intelligence and Emerging Technologies Partnership Series – Part Two of Three Sheppard, Mullin, Richter & Hampton LLP
Jul
12
2019
What’s in the Bottle? FDA Announces New Blockchain Pilot Program for Tracking Drug Distribution Sheppard, Mullin, Richter & Hampton LLP
Jul
26
2019
Is Prescription Drug Pricing The Cure For Partisanship? Sheppard, Mullin, Richter & Hampton LLP
Feb
14
2023
FDA Issues Warning Letter to RightEye, LLC For Misbranding and Adulteration Sheppard, Mullin, Richter & Hampton LLP
Apr
10
2023
FDA To Require Demonstration of Cybersecurity Safeguards for Pre-Market Submissions of Certain Medical Devices Sheppard, Mullin, Richter & Hampton LLP
Jun
4
2023
FDA Cracking Down on Unapproved HCT/Ps with Fourth Untitled Letter of 2023 Sheppard, Mullin, Richter & Hampton LLP
Jun
11
2023
Is this “Good-Bye” to the Two-Year Mandatory Minimum in Healthcare Fraud Cases? Sheppard, Mullin, Richter & Hampton LLP
Jun
14
2023
Healthier Choices Management Corp. v. Philip Morris USA, Inc. No. 22-1268 (Fed. Cir. Apr. 12, 2023) Sheppard, Mullin, Richter & Hampton LLP
Dec
10
2019
FDA Issues Warning Letters to 15 Companies, Consumer Update on CBD Safety Sheppard, Mullin, Richter & Hampton LLP
Aug
17
2023
Fifth Circuit Rules to Reinstate Abortion Pill Restrictions Sheppard, Mullin, Richter & Hampton LLP
Oct
9
2023
At HLTH 2023: General Catalyst’s HATCo Introduces a Radically Ambitious and Transformative Model for Healthcare Sheppard, Mullin, Richter & Hampton LLP
Apr
15
2020
FCPA Landmines Beneath the Surface of the COVID-19 Crisis - May 6 Sheppard, Mullin, Richter & Hampton LLP
May
5
2020
IP Protection and the Open COVID Cure Chase Sheppard, Mullin, Richter & Hampton LLP
Jan
2
2024
The Intertwining Nature of Motivation to Combine and Reasonable Expectation of Success Sheppard, Mullin, Richter & Hampton LLP
Jan
29
2024
2024 Top-of-Mind Issues for Life Sciences Companies Sheppard, Mullin, Richter & Hampton LLP
Feb
6
2024
FDA’s Office of Prescription Drug Promotion Issues Its First Untitled Letter of the Year to Novartis for Misleading Statement Relating to KISQALI® Sheppard, Mullin, Richter & Hampton LLP
Feb
20
2024
New Bills Being Served Up That May Soon Impact Food Retailers and Manufacturers Sheppard, Mullin, Richter & Hampton LLP
Mar
19
2024
Time to Refresh? FDA Issues Draft Guidance on Key Information and Informed Consent Sheppard, Mullin, Richter & Hampton LLP
Oct
20
2020
California Governor Pulls the Plug on Genetic Information Privacy Act Sheppard, Mullin, Richter & Hampton LLP
Mar
29
2021
FDA Announces First Ever Facility Fees for OTC Drug Manufacturers Sheppard, Mullin, Richter & Hampton LLP
Apr
15
2021
Breaking Down FDA’s New Remote Monitoring Strategy Sheppard, Mullin, Richter & Hampton LLP
Nov
16
2010
Proposition 23's Failure Means Full Speed Ahead on AB 32 Sheppard, Mullin, Richter & Hampton LLP
May
8
2021
FDA Proposes Risk-Based and Remote Inspection Strategies in New Report Sheppard, Mullin, Richter & Hampton LLP
Feb
9
2018
Temporal Proximity Is Not Enough: Third Circuit Nixes FCA/Anti-Kickback Suit For Failure To Link Alleged Scheme to Claims Sheppard, Mullin, Richter & Hampton LLP
Jul
30
2013
Food and Drug Administration (“FDA”) Draft Guidance For Industry On Pre-Launch Activities Importation Requests: Dead On Arrival? Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins